It is also used in combination with chemotherapy in patients with previously untreated follicular & diffuse large B‐cell, CD20 positive B‐cell NHL, and as single‐agent maintenance therapy in patients who achieved a complete/partial response to Rituxan®. Here, MS4A1 is linked to B-cell non-Hodgkin lymphoma.